C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart C—Abbreviated Applications

21 C.F.R. § 314.98 (2026)

Postmarketing reports

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 2009–2020 11citing cases
At a glance

Courts have cited this section in 11 opinions since 2009.

(a) Each applicant having an approved abbreviated new drug application under § 314.94 that is effective must comply with the requirements of § 314.80 regarding the reporting and recordkeeping of adverse drug experiences.

(b) Each applicant must make the reports required under § 314.81 and section 505(k) of the Federal Food, Drug, and Cosmetic Act for each of its approved abbreviated applications.

[79 FR 33089, June 10, 2014]
The 11 cases that cite 21 C.F.R. § 314.98 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
YELLOWGaeta v. Perrigo Pharm. Co., 630 F.3d 1225 (9th Cir. 2011).
cites § 314.98 4×cited by 15 cases
Vacated (GVR) by L. Perrigo Co. v. Gaeta (2011): the Supreme Court's order in this case remanded it for further consideration; read the decision on remand before relying on it.
Where it cites § 314.98
“80 (a), (c) (NDA holders); 21 C.F.R. § 314.98 (a) (ANDA holders). Similarly, both sets of manufacturers must submit annual reports that include, inter alia, a “brief summary of significant new information from the previous year that might affect the safety, effectiveness, or…”
2
REDMensing v. Wyeth, Inc., 588 F.3d 603 (8th Cir. 2009).
cites § 314.98 2×cited by 56 cases
Reversed by the U.S. Supreme Court in this case: PLIVA, Inc. v. Mensing (2011).
Where it cites § 314.98
“Further, 21 C.F.R. § 314.98 requires that generic manufacturers follow the same record keeping and reporting of adverse drug experiences post marketing that name brand manufacturers must undertake.”
The case’s holding
A brand name manufacturer owes no duty of care to warn of risks that are legally mandated by generic label requirements (stretching the concept of foreseeability too far).
Later courts cite it for
“intend to communicate with their customers, not the customers of their competitors.” · 3 citing courts
3
GREENBartlett v. Mut. Pharm. Co., 659 F. Supp. 2d 279 (D.N.H. 2009).
cites § 314.98 2×cited by 21 cases
Where it cites § 314.98
“at 17983 (codified as amended at 21 C.F.R. § 314.98 (a)). Section 314.80 requires an applicant to report (A) “each adverse drug experience that is both serious and unexpected .”
The case’s holding
Federal drug-labeling law does not impliedly preempt state-law failure-to-warn claims against a generic drug manufacturer, because federal rules allow post-approval labeling changes that could have strengthened the warnings.
Later courts cite it for
“the fda's remarks in proposing and promulgating these regulations” · 2 citing courts
4
REDDemahy v. Actavis, Inc., 593 F.3d 428 (5th Cir. 2010).
cites § 314.98 1×cited by 37 cases
Reversed by the U.S. Supreme Court in this case: PLIVA, Inc. v. Mensing (2011).
Where it cites § 314.98
“57(c)(6) (explaining that evidence must be "reasonable” in order to change a label's warnings and precautions); Id. at § 201.57(c)(7) (explaining that there must be "some basis to believe” in order to change a label's discussion of adverse reactions).”
The case’s holding
Federal regulatory requirements for generic drugs do not preempt state law failure-to-warn claims because manufacturers can comply with both sets of laws through available regulatory processes.
Later courts cite it for
“generic manufacturers cannot send 'dear doctor' letters without prior fda approval” · 2 citing courts
5
GREENBartlett v. Mut. Pharm. Co., 731 F. Supp. 2d 135 (D.N.H. 2010).
cites § 314.98 1×cited by 20 cases
Where it cites § 314.98
“80 (b), which requires brand-name drug manufacturers to “develop written procedures for the surveillance, receipt, evaluation, and reporting of post-marketing adverse drug experiences to FDA,” applies equally to generic drug manufacturers by virtue of 21 C.F.R. § 314.98 (a),…”
The case’s holding
A manufacturer avoids liability for defective design if it proves the drug is unavoidably unsafe and includes an adequate safety warning.
Later courts cite it for
“avoid liability for defective design if it can prove, as an affirmative defense, that sulindac is unavoidably unsafe and had an adequate safety warning.” · 3 citing courts
6
GREENFulgenzi v. Wyeth, Inc., 686 F. Supp. 2d 715 (N.D. Ohio 2010).
cites § 314.98 1×cited by 7 cases
Where it cites § 314.98
“at 609 (citing 21 C.F.R. § 314.98 ). It further drew from the FDA's own comment noting that "ANDA applicants [must] submit a periodic report of adverse drug experiences even if the ANDA applicant has not received any adverse drug experience reports or initiated any labeling…”
Later courts cite it for
“multiple state law tort claims, including several claims sounding in fraud” · 3 citing courts
7
NO FLAGBartlett v. Mut. Pharm., 2010 DNH 112 (D.N.H. 2010).
cites § 314.98 1×cited by 3 cases
Where it cites § 314.98
“80 (b), which reguires brand-name drug manufacturers to "develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to FDA," applies egually to generic drug manufacturers by virtue of 21 C.”
8
REDWyeth, Inc. v. Danny Weeks, 159 So. 3d 649 (Ala. 2014).
cites § 314.98 2×cited by 28 cases
Superseded by statute on other grounds (Ala. Code § 6-5-530(a)): 3 citing opinions limit it to other grounds and 2 say superseded outright.
Where it cites § 314.98
“21 C.F.R. § 314.98 . However, brand-name manufacturers and generic manufacturers have different federal drug-labeling responsibilities.”
The case’s holding
A prescription drug manufacturer fulfills its duty to warn ultimate users by providing adequate warnings to the learned intermediaries who prescribe the drug.
Later courts cite it for
“in short, the patient must show that, but for the false representation made in the warning, the prescribing physician would not have prescribed the medication to his patient.” · 4 citing courts
9
GREENBartlett v. Mut. Pharm., 2009 DNH 144 (D.N.H. 2009).
cites § 314.98 2×cited by 0 cases
Where it cites § 314.98
“at 17983 (codified as amended at 21 C.F.R. § 314.98 (a)). Section 314.80 requires an applicant to report (A) “each adverse drug experience that is both serious and unexpected .”
10
NO FLAGRaymond J Collette v. Wyeth Pharm., Inc., No. 3:16-cv-01034 (N.D. Cal. June 22, 2020).
cites § 314.98 1×cited by 0 casesunknown
Where it cites § 314.98
“80 (c); 21 C.F.R. § 314.98 ). The fifth cause of action alleges 16 “strict liability – manufacturing defect,” and is based on allegations that “the Manufacturer 17 Defendants failed to comply with the FDA’s Good Manufacturing Practices with regard to 18 Packaging and Labeling…”
11
REDGladys Mensing v. Wyeth, Inc., No. 08-3850 (8th Cir. Nov. 27, 2009).
cites § 314.98 1×cited by 0 cases
Where it cites § 314.98
“Further, 21 C.F.R. § 314.98 requires that generic manufacturers follow the same record keeping and reporting of adverse drug experiences post marketing that name brand manufacturers must undertake.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200920142020

One bar per year. Tallest: 4 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.N.H.48th Cir.2Ala.15th Cir.19th Cir.1N.D. Cal.1N.D. Ohio1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com